Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Amortizatization of Intangibles: 2015-2023

Historic Amortizatization of Intangibles for Coherus Oncology (CHRS) over the last 9 years, with Dec 2023 value amounting to -$428,000.

  • Coherus Oncology's Amortizatization of Intangibles fell 153.50% to -$428,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $2.4 million, marking a year-over-year decrease of 62.57%. This contributed to the annual value of $4.2 million for FY2024, which is 72.79% up from last year.
  • As of Q4 2023, Coherus Oncology's Amortizatization of Intangibles stood at -$428,000, which was down 171.21% from $601,000 recorded in Q3 2023.
  • In the past 5 years, Coherus Oncology's Amortizatization of Intangibles ranged from a high of $3.7 million in Q1 2022 and a low of -$428,000 during Q4 2023.
  • In the last 3 years, Coherus Oncology's Amortizatization of Intangibles had a median value of $991,000 in 2021 and averaged $1.1 million.
  • As far as peak fluctuations go, Coherus Oncology's Amortizatization of Intangibles surged by 269.23% in 2022, and later slumped by 153.50% in 2023.
  • Quarterly analysis of 5 years shows Coherus Oncology's Amortizatization of Intangibles stood at $613,000 in 2019, then surged by 61.34% to $989,000 in 2020, then rose by 11.93% to $1.1 million in 2021, then declined by 27.73% to $800,000 in 2022, then slumped by 153.50% to -$428,000 in 2023.
  • Its last three reported values are -$428,000 in Q4 2023, $601,000 for Q3 2023, and $895,000 during Q2 2023.